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Abstract 
Little is known about the host factor in the response to PRRSV vaccination. For this purpose, piglets were immunized 
with a commercial PRRSV‑live vaccine and classified as high responders (HR) or low responders (LR) as regards to the 
frequencies of virus‑specific IFN‑γ‑secreting cells. Six weeks post vaccination, PBMCs isolated from three individuals 
with the most extreme responses in each HR and LR groups and 3 unvaccinated controls, were either stimulated with 
phytohaemagglutinin, challenged with the vaccine or mock treated for 24 h, prior conducting transcriptional studies, 
gene ontology and pathway analyses. The LR group had very low neutralizing antibody levels and showed a higher 
number of down‑regulated transcripts compared with the HR group (FDR < 0.2, P < 0.001). Down‑regulated genes 
encoded chemoattractants, proinflammatory cytokines and the interferon‑inducible GBP family, and showed enrich‑
ment in wounding (FDR < 3.6E‑13), inflammation (FDR < 8E‑12), defence (FDR < 8.7E‑09) and immunity (FDR < 7.6E‑
08), suggesting immune response impairment. In the HR group, down‑regulated genes were involved in protein 
transport (FDR < 4.77E‑03), locomotory behavior (FDR < 5.47E‑3), regulation of protein localization (FDR < 1.02E‑02), 
and regulation of TNF superfamily member 15 and miR181. In contrast, the HR group presented up‑regulated tran‑
scripts associated with wounding (FDR < 4.95). Moreover, IFN‑γ was predicted to be an inhibited upstream regulator 
since IFN‑γ pathways were associated with higher number of down‑regulated genes in the LR (n = 40) than the HR 
(n = 10). Divergent responses to PRRSV‑vaccination may be the result of the genetic background of the host.
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Introduction
Porcine reproductive and respiratory syndrome (PRRS) 
is arguably the most endemic infectious disease chal-
lenge for the pig industry and causes very significant 
economic losses worldwide [1, 2]. The causative agent 
is an enveloped, single-stranded 15-kb positive-sense 
RNA virus belonging to the Arteriviridae family in the 
order Nidovirales [3] known as PRRS virus (PRRSV). 
The extensive genetic diversity characteristic of PRRSV 
encodes considerable antigenic diversity which presents 
a highly variable challenge to the host’s immune system 
[4–12]. Moreover PRRSV is known to modify the host’s 
innate immune response, particularly by inhibiting type-
I interferons (IFNs), affecting cytokine production or 
by down regulating toll-like receptor (TLRs) expression 
[13–19].
The most widely used strategy for reducing the inci-
dence and limiting the impact of PRRSV-infection 
damages is vaccination. Several commercial vaccines 
(including live attenuated and inactivated) are available 
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on the market but their efficacies are considered to be at 
best partial as they cannot provide full protection against 
the wide diversity of PRRSV strains circulating in the field 
[20, 21]. PRRSV vaccines are routinely applied to breed-
ing herds to prevent reproductive problems but the ben-
eficial effect of vaccination to piglets is still controversial. 
After immunization of a group of pigs with a given vac-
cine, a variety of immune response are often generated 
among pigs and only some of them are being protected 
against infection. Thus, the genetics of the host (pigs) and 
of the pathogen (PRRSV) appear to play an important 
role on the efficacy of vaccination in the control of PRRS.
The interaction of PRRSV with the immune system is 
believed to be of critical importance for defining immu-
nological and clinical outcomes of the infection and, 
along with other factors, is associated with an inefficient 
development of the adaptive immunity. The prototypical 
adaptive response to PRRSV is characterized by a weak 
and delayed production of neutralizing antibodies and by 
relatively low levels of IFN-γ producing T-cells [22, 23]. 
Moreover, there is increasing evidence that the genetic 
variation of both host and virus also have impacts on the 
response to infection [24–29].
Therefore, in order to understand immune responses 
to PRRSV infection and/or vaccination it is necessary 
to examine both sources of variation: host (pig) and 
pathogen (PRRSV). Analysis of the host response using 
transcriptional profiling of pigs with different immune 
status against PRRSV may help to understand why vac-
cines offer only partial protection. The objective of this 
study was to identify transcriptional signals and molecu-
lar pathways associated with responses to a PRRSV vac-
cine [30]. Systems biology approaches have been used 
successfully to identify early gene signatures that predict 
immune responses in humans vaccinated with the live 
attenuated vaccine YF-17D against yellow fever virus 
and inactivated seasonal influenza vaccine against influ-
enza virus with accuracy [31, 32]. In order to explore this 
approach for PRRSV vaccines pigs were vaccinated with 
a modified live (ML) PRRSV vaccine and later classified 
into two groups, namely “high responders” (HR) and “low 
responders” (LR) on the basis of the frequencies of virus-
specific interferon-γ secreting cells (IFN-γ SC). Subse-
quently, the humoral response against the virus and the 
transcriptional profiles of peripheral blood mononuclear 
cells (PBMC) of both groups were examined in order to 
identify genes, molecular functions and biological path-
ways associated with the vaccine response.
Materials and methods
Animals and study design
Twenty-two healthy four-week-old Landrace  ×  Large 
White PRRSV-negative pigs (as determined by serology 
and RT-PCR) were vaccinated intramuscularly with 
a genotype-1 commercial ML vaccine (Pyrsvac-183) 
according to the manufacturer’s instructions. Pigs were 
followed up for 42 days after vaccination. In parallel, 10 
control pigs were subjected to a mock vaccination with 
sterile saline solution (SS). Pigs were bled for immuno-
logical determinations at day 0 (pre-vaccination) and 
then once a week post-vaccination (PV) for 6 weeks: days 
7, 14, 21, 28, 35 and 42 PV (Figure 1).
Peripheral blood mononuclear cell isolation
Heparinized blood samples were used for separation of 
PBMC by density-gradient centrifugation with Histo-
paque 1.077 (Sigma). PBMC were subsequently cultured 
using RPMI medium supplemented with 10% foetal calf 
serum (FCS) (Invitrogen, Madrid, Spain), 1  mM non-
essential amino acids (Invitrogen), 1  mM sodium pyru-
vate (Invitrogen), 5  Mm 2-mercaptoethanol (Sigma), 50 
000 IU penicillin (Invitrogen), 50 mg streptomycin (Inv-
itrogen) and 50 mg gentamicin (Sigma) (complete RPMI). 
Trypan blue was used to assess cell viability.
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Figure 1 Scheme of the study design. Firstly, pigs were dis‑
tributed in two groups: intramuscularly (IM) inoculated either with 
Pyrsvac‑183 vaccine (n = 22) or sterile solution (SS) as unvaccinated 
control group (n = 10). Animals were followed‑up from day 0 (pre‑
vaccination) to 6 weeks post‑vaccination (PV). Blood and sera sam‑
ples were collected every week for immunological determinations 
(ELISPOT virus‑specific IFN‑γ secreting cells ‑SC‑, neutralizing antibod‑
ies ‑NA‑ assays, ELISA total Ab). At week 6 PV, vaccinated pigs with 
the highest and lowest average scores for the IFN‑γ‑SC were divided 
into the High Responder (HR) and the Low Responder (LR) groups, 
respectively. At this last time point, gene expression was analysed 
in PBMCs from the LR (n = 3), HR (n = 3) and control unvaccinated 
(n = 3) pigs using Affymetrix microarray platform. *Immunological 
studies: cellular and humoral immune responses (serum, PBMCs). 
**Transcriptional studies (microarray analysis using the PBMCs) HR: 
high responders; LR: low responders; †The highest and the ††lowest 
average levels of virus‑specific IFN‑γ secreting cells through the time 
course of the study. Pre‑vaccination (Pre‑V). Post‑vaccination (PV). 
Intramuscular (IM). Sterile Saline solution (SS).
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ELISPOT assays
ELISPOT assays were performed as described previ-
ously [12, 33] using commercial mAbs (P2G10 and bio-
tin P2C11; BD Biosciences Pharmingen). Peripheral 
blood mononuclear cells (PBMC) were stimulated for 
24 h (5 × 105 PBMC/well, in triplicate) with the ML vac-
cine strain at a multiplicity of infection (m.o.i.) of 0.1 as 
a recall antigen, phytohaemagglutinin (PHA, 10  μg/mL) 
or culture medium. To calculate the frequencies of virus 
specific IFN-γ-SC, average counts of spots in unstimu-
lated wells were subtracted from average counts obtained 
in antigen stimulated wells. Results were expressed as the 
number of PRRSV-specific IFN-γ-SC per 5 × 105 PBMC.
Three pigs with the highest virus-specific IFN-γ-SC 
average responses throughout the timecourse of the 
study, designated as HR (High responders), and 3 pigs 
with the lowest average levels, or LR (Low responders), 
were selected for further analysis (Figure 1). Average HR 
and LR frequencies at 21 days PV were 26 ± 3/5 × 105 
cells versus 12  ±  5.6/5  ×  105 cells and at 42  days, 
54.3 ± 8.1/5 × 105 cells versus 22.3 ± 4.5/5 × 105 cells 
(Figure  2). Three healthy unvaccinated pigs (SS) were 
randomly taken as a control group.
Humoral response
A commercially available ELISA (Idexx PRRS X3 Ab 
Test) was used for measuring non neutralizing anti-
PRRSV antibodies in blood samples taken at the different 
time-points of the study. Results were reported as a ratio 
of optical densities between the results of a given sam-
ple and the positive control (S/P ratio) included in the kit 
(cut-off: S/P ≥ 0.4). All samples were tested the same day 
and in the same batch of plates.
In parallel, homologous (against the vaccine virus) neu-
tralizing antibodies (NA) titers were determined in a viral 
neutralization test (VNT). The VNT assays were done 
in MARC-145 cells using log2 serial dilutions (from 2−1 
to 2−8) as described before running samples in duplicate 
[34, 35].
In vitro treatment of peripheral blood mononuclear cells
At 6  weeks PV (Figure  1), PBMC isolated from the 
selected pigs of each group (HR and LR) and from unvac-
cinated pigs were seeded at 5 × 105 cells/well in 96 well-
plates and were cultured in triplicates with complete 
RPMI alone (negative controls), complete RPMI with 
phytohaemagglutinin (PHA, 10 μg/mL, positive controls) 
or the PRRSV vaccine strain (m.o.i. 0.1, specific stimulus) 
for 24 h. After that period, cells were harvested, centri-
fuged and cell pellets were resuspended in 1 mL of Trizol 
(Life Technologies) and frozen at −80  °C until process-
ing for RNA extraction, microarray and downstream 
analysis.
RNA extraction
Total RNA from PBMC of selected group pigs at 6 weeks 
PV was extracted using Trizol (Invitrogen, Paisley UK) 
according to the manufacturer’s instructions and was 
later purified using the Qiagen RNeasy minikit (Qiagen, 
Crawley, UK). RNA was eluted from the spin column 
in 30  µL of RNase-free water and stored as aliquots at 
−80 °C. The quantity and quality of RNA were assessed 
using a Nanodrop spectrophotometer (NanoDrop Tech-
nologies Inc, Wilmington, DE, USA) and Agilent 2100 
bioanalyser (Agilent Technologies, Palo Alto, CA, USA) 
respectively.
Microarray platform and data analysis
The extracted RNA was then analysed using the Affyme-
trix Snowball GeneChip® [36]. This GeneChip comprises 
23 937 probe sets that interrogate approximately 23 256 
transcripts from 20  201 Sus scrofa genes. Sense-strand 
cDNA was generated from total RNA (500 ng) subjected 
to two rounds of amplification (Ambion® WT Expression 
Kit). The resulting cDNA was used for biotin labelling 
and fragmentation according to the Affymetrix Gene-
Chip® WT Terminal Labelling and Hybridization pro-
tocol (Affymetrix UK, High Wycombe). Biotin-labelled 
fragments of cDNA (5.5 μg) were hybridized to Affyme-
trix Snowball arrays using the Affymetrix HybWashStain 
kit and following the manufacturer’s recommendations. 
After hybridization, the arrays were washed and stained 
using the Affymetrix Fluidics Station 450 and then 
scanned in an Affymetrix 7G scanner. Image generation 
and the resulting CEL files for analysis were produced in 
AGCC—Affymetrix GeneChip Command Console Soft-
ware. Initial QCs were performed in Expression Console. 
All microarray data used in the analyses herein are avail-
able from the Array Express repository [37]. The Affym-
etrix.CEL files were imported into the Partek Genomics 
Suite software package version 6.13.0213 (Partek, St. 
Louis, USA) for data analysis. Transcriptional responses 
were normalised to those from unvaccinated pigs prior 
to running an ANOVA analysis of the data (Additional 
file  1). Up-regulated and down-regulated differentially 
expressed transcripts in HR and LR were selected for 
further consideration if the false discovery rate (FDR) 
was ≤0.2.
For network analysis, the normalised array data 
were uploaded to the software Biolayout Express3D 
as described previously [36, 38]. Expression variations 
across treated groups were generated using the gplots 
package in R.
Quantitative real time RT‑PCR validation (qRT‑PCR)
The differential expression of several selected genes, 
as identified from the microarray data, was verified at 
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various time points using qRT-PCR. Reverse transcrip-
tion was performed as described previously [26, 27]. 
Briefly, one microgram of total RNA was reverse tran-
scribed using a TaqMan kit (Applied Biosystems, Foster 
City, CA, USA). For qRT-PCR, Platinum SYBR Green 
PCR SuperMix UDG was used, as described above. The 
qRT-PCR was performed with a Stratagene MX3000P 
(Stratagene, La Jolla, CA, USA). In Table  1 is showed 
the information about primer sequences of the selected 
genes. Samples were tested in triplicate, GAPDH served 
as the housekeeping gene and results were calculated as 
described previously [26, 27].
Gene ontology and pathway analysis
Gene ontology and pathway analysis were carried out 
using DAVID bioinformatics resources [39] and Ingenu-
ity pathway analysis [40], respectively. In particular for the 
identification of upstream regulators using IPA, expres-
sion datasets for the HR and the LR pigs were analysed 
independently with Fisher’s exact test as described by the 
software. The activation z-score was used to infer the state 
of activation of upstream regulators based on a compari-
son with a model that assigns random regulations. The P 
value overlap, which indicates possible upstream regula-
tors, represents the significance of the overlap between 
the dataset genes identified and the known targets of 
transcriptional regulators. Differences were considered 
significant with P-value <0.05 and activation Z-score ≥2.
Statistical analysis
Comparison of frequencies of IFN-SC, S/P ratios or 
titres of NA between groups was done using StatsDirect3 
(v3.0.97) and the Kruskal–Wallis test. The coefficient of 
correlation (R2) between microarray and qRT-PCR tech-
niques was produced by plotting the relative level of gene 
expression as assessed by microarray against the tran-
script levels generated by qRT-PCR.
Results
Characterization of the humoral response in HR and LR 
pigs
When the S/P ratios, corresponding to non-neutral-
izing antibodies (NA), were examined, values were 
always higher (p  <  0.05) in the LR vaccinated group 
compared to the HR vaccinated group from day 14 PV 
onwards (Figure  3A). In contrast, HR had an earlier 
and stronger NA response to PRRSV vaccine at 28, 35 
and 42  days PV in comparison to the LR group (Fig-
ure 3B). Regarding the viremia, CT means for HR were 
28.3 ± 1.8 (day 14); 27.8 ± 1.7 (day 21); 29.9 ± 3.9 (day 
28); and 34.0 ±  5.0 (day 35). For LR, CT means were 
30.9 ± 3.4 (day 14); 28.4 ± 5.7 (day 21); 32.9 ± 1.8 (day 
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Figure 2 Levels of IFN-γ secreting cells (SC) in all vaccinated pigs against the PRRSV vaccine strain at different time-points post-
vaccination by ELISPOT. Vaccinated pig groups were classified according to the intensity of the cellular mediated immune responses against the 
vaccine: “High responder” (HR) group comprised by pigs with the highest levels of IFN‑γ‑SC responses (black circle), the “Low responder” (LR) group 
with pigs with the Lowest IFN‑γ‑SC levels (grey circle) and other vaccinated pigs with intermediate IFN‑γ‑SC responses (white circle). The unvacci‑
nated control group was not shown in the graph since all animals showed no specific response. *Statistical differences (P < 0.05).
Page 5 of 12Ait‑Ali et al. Vet Res  (2016) 47:104 
28); and 34.7 ± 1.6 (day 35). All animals were negative 
for PRRSV vaccine virus in blood at day 42, with the 
exception of one animal of the LR group that showed 
a CT = 35 that corresponds to 1.2–1.3 log10 genomic 
equivalences per mL.
Host transcript regulation during PRRSV vaccine challenge
From the total number of evaluated genes, 29 and 127 
transcripts were identified as differentially expressed in 
the mock stimulated PBMC cultures of HR and LR vac-
cinated pigs, respectively (ANOVA FDR <0.2, P < 0.001). 
The proportion of genes which showed reduced levels 
of expression either in the presence of PHA treatment 
or in mock-stimulated cultures was larger in the LR 
vaccinated group compared with the HR (Table  2). In 
contrast, PBMCs from HR and LR vaccinated pigs and 
treated in vitro with the vaccine did not harbor statisti-
cally different regulated transcripts when compared to 
the controls (Table 2). To investigate further this obser-
vation, we examined differential expression using net-
work analysis with Biolayout Express3D. Nine probesets 
mapping to 7 unique gene symbols showed a differential 
expression of  >2 Log fold change between the PBMCs 
of LR and HR vaccinated pigs and unvaccinated control 
groups after vaccine stimulation (Figure  4, red squared 
section). Most of them showed increased expression in 
LR and HR groups compared to controls. Among these 
genes we found three chemokines, CXCL9, CXCL10 and 
CXCL11, which activate monocytes and T-lymphocytes, 
two Cytochromes, CYP3A46 and CYP3A29 of which the 
latter has been reported to be regulated by interferon 
[41], and OAS1 which is an interferon-induced antiviral 
enzyme [42].
Validation of differentially regulated transcripts using 
quantitative real time PCR (qRT‑PCR)
Nine genes for which changes in transcript levels had 
been observed were selected for validation by qRT-PCR 
analysis. The selection criteria were: (i), differential regu-
lation in the both groups (fold change ≥2.0, FDR ≤0.2) 
and ii), involvement in immune functions such as inflam-
mation, antiviral responses and cell growth and recruit-
ment molecules. Thus we selected the following genes: 
GBP2, IL1A, IL8, CCL4, SAA1, IGF1, CCL2, IL1B and 
LTBP1. The results showed positive correlation coeffi-
cients between the microarray and qRT-PCR techniques 
in the HR (R2 = 0.76) and LR (R2 = 0.86) groups (Addi-
tional file 2).
Gene ontology analyses
Transcripts differentially regulated in the HR and LR 
vaccinated groups (Additional file 1) were analysed with 
respect to their biological processes, molecular func-
tions and cellular (Additional file  3). Interestingly, the 
LR vaccinated group presented a higher number of 
down-regulated genes (6–25 genes) per biological pro-
cesses category than the HR vaccinated (3–6 genes) but 
in a more restricted range of categories (9 categories 
vs 18 categories in the HR) (Figure  5). In the LR group 
mostly down-regulated transcripts showed significant 
fold functional enrichment (FFE) in 9 biological pro-
cess involved in inflammation and immune responses as 
Table 1 List of the genes selected for the quantitative real time RT-PCR validation
Gene name Sequence of the primers Ensembl ID Primer position Description
GBP2 F: CCTGTGGTGGTGGTGGTTAT ENSSSCG00000006923 Exon 3–4 Guanylate binding protein 2, interferon‑inducible
R: AGATGCCCTTCGTGTGAGAC
IL1A F: CAAGGACAGTGTGGTGATGG ENSSSCG00000008090 Exon 4–5 Interleukin 1, alpha
R: GTTGCTGATCTGGGCTTGAT
IL8 F: CCTTCTTGGCAGTTTTCCTG ENSSSCG00000008953 Exon 1–2 Interleukin 8
R: AATTTGGGGTGGAAAGGTGT
CCL4 F: CATGAAGCTCTGCGTGACTG ENSSSCT00000019264 Exon 1–2 Chemokine (C–C motif ) ligand 4
R: ACGGTGTATGTGAAGCAGCA
SAA1 F: ACTATGATGCTGCCCAAAGG ENSSSCT00000014601 Exon 1–2 Serum amyloid A1
R: ACTCCGTGGCCACTGTCTC
IGF1 F: AGTTCGTGTGCGGAGACAG ENSSSCT00000000935 Exon 2–3 Insulin‑like growth factor 1
R: GCCTCCTCAGATCACAGCTC
CCL2 F: CTTCTGCACCCAGGTCCTT ENSSSCT00000019290 Exon 1–2 Chemokine (C–C motif ) ligand 2
R: TGCTGCTGGTGACTCTTCTG
IL1B F: AGTGGAGAAGCCGATGAAGA ENSSSCT00000008861 Exon 4–5 Interleukin 1, beta
R: CATTGCACGTTTCAAGGATG
LTBP1 F: GGGAACACCACCACTCTCAT ENSSSCT00000009313 Exon 1–2 Latent transforming growth factor beta binding protein 1
R:TTGTCCCTTGAACTGCACTG
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follow: response to wounding (8.6 FFE, FDR < 3.6E-13), 
inflammatory response (11.2 FFE, FDR < 8E-12), defence 
response (6.5 FFE, FDR < 8.7E-09) and immune response 
(5.4 FFE, FDR < 7.6E-08) (Additional file 3). Our results 
suggest that two broad molecular functions involved in 
chemokine receptor binding/activity and cytokine activ-
ity were down-regulated in LR and included genes encod-
ing a wide range of chemoattractants (CCL2, CCL17, 
CCL22 and CCL23) and the proinflammatory cytokines 
IL1A and ILIB and receptor antagonist IL1RN. Among 
the most down-regulated genes involved in immune 
response included several members of interferon-
inducible guanylate binding protein (GBP) family GBP2 
(13.1 fold), GBP4 (4.6 fold) and GBP6 (9.9 fold). Finally, 
whereas no significant function dominated the category 
of up-regulated genes for the LR group, the greatest fold 
changes were observed for insulin-like growth factor 1 
(IGF1, 13.0 fold).
In the HR vaccinated group, although the number 
of genes that were down-regulated per category was 
lower than the LR, the number of biological processes 
involved was twice as great as in the LR vaccinated pigs 
(Figure  5). The biological functional fold enrichments 
were associated with the regulation of protein transport, 
locomotory behaviour and regulation of protein locali-
zation which were enriched 42.4 FFE (FDR < 4.77E-03), 
21.2 FFE (FDR < 5.47E-3) and 35 FFE (FDR < 1.02E-02), 
respectively. It is noteworthy that down-regulated genes 
in this group harboured the same trend than in the LR 
vaccinated group. For example SAA1, CCL3L1 and CCL4 
were down-regulated group (Additional file 3). Also tran-
scripts encoding for the tumor necrosis factor (TNF) 
superfamily member 15 (TNFSF15) (−2.2 fold, P < 7.9E-
05) and miR181 (−2.4 fold, P  <  2.1E-04) appeared spe-
cifically down-regulated in a statistical significant 
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Figure 3 Levels of humoral immune response in sera of High 
and Low responders after PRRSV vaccination. A Total non‑
neutralizing anti‑PRRSV antibodies by ELISA (Idexx PRRS X3 Ab Test). 
Cut‑off: S/P ≥ 0.4. *Statistical differences by Kruskal–Wallis (P < 0.05). 
B Homologous Neutralizing Antibody (NA) titers in the viral neutrali‑
zation test done in MARC‑145 cells using log2 serial dilutions. Number 
of pigs presenting NA titers out of the total pigs is represented 
in brackets above the corresponding bar. *Statistical differences 
(P < 0.05). All samples from the control unvaccinated group and 
samples at day 0 post‑vaccination of HR and LR groups were negative 
for all tests.
Table 2 Summary of the number of transcript regulated in PBMCs at 6 weeks post-vaccination
Non‑redundant transcripts with ANOVA P value < 0.001 and a FDR < 0.2 were showed. Details of the genes for which changes in transcript levels were observed are 
presented in Additional file 1 which shows gene symbols, P values and fold changes.
ns: no statistically significant differences were detected between groups, HR: High responder group, LR: Low responder group.
FDR < 0.2, P < 0.001.
Group Treatment Comparator Up‑regulated transcripts
(n)
Down‑regulated transcripts
(n)
Total genes
(N)
High responder (HR) Medium (mock) Unvaccinated pigs 7 22 29
Low responder (LR)
P
Medium (mock) Unvaccinated pigs 18 109 127
High responder (HR) PHA Unvaccinated pigs + PHA 3 11 14
Low responder (LR)
P
PHA Unvaccinated pigs + PHA 4 20 24
High responder (HR) PRRSV‑vaccine Unvaccinated pigs + vaccine ns ns ns
Low responder (LR) PRRSV‑vaccine Unvaccinated pigs + vaccine ns ns ns
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manner. In contrast, up-regulated transcripts in the HR 
vaccinated group were barely dominated by a biological 
function that was the response to wounding (50.2 FFE, 
FDR < 4.95) involving purinergic P2Y G-protein coupled 
receptor (P2RY12), vanin1 (VNN1) and IGF1 (Additional 
file 3).
Upstream regulators using Ingenuity pathway analysis 
(IPA)
To identify the cascade of upstream transcriptional regula-
tors that could explain the observed gene expression data 
for the HR and LR vaccinated groups we performed in sil-
ico analysis using IPA. Table 3 shows top 10 upstream reg-
ulators, each predicted to act upon different sets of target 
molecules, likely mediating different biological effects. HR 
and LR datasets shared a similar set of inhibited upstream 
regulators (P  <  1E-06) with the exception of IL1A and 
STAT3 which were specific to the LR vaccinated group 
(Table  3; Additional file  4). It is noteworthy that IFNG 
was identified as an inhibited upstream regulator with 
a greater activation z-score in the LR vaccinated group 
(−4.4, P value  <  3.36E-20) than in the HR group (−2.4, 
P value  <  1.26E-06). The results of the in silico analysis 
of the relationship between IFNG and target genes show 
that 10 and 40 predicted relationships were identified with 
IFNG and target genes in the HR and LR vaccinated group, 
respectively (Figure 6). Thus, IFNG was predicted to be an 
inhibited upstream regulator to explain the trend of regu-
lation in HR and LR vaccinated groups. 
Discussion
It is increasingly recognized that the control of PRRS 
will require a global approach that will consider relevant 
factors of the pathogen, the host and the environment. 
Although valuable tools, current PRRSV vaccines are not 
fully efficacious and some vaccinated animals may still 
become infected [43]. It is thought that this partial lack of 
efficacy may be attributable to the genetic and antigenic 
diversity of the virus. However, several studies have high-
lighted that there is high inter-individual variability in 
the development of the immune response and protection 
after vaccination with a PRRSV vaccine [12, 44, 45] which 
may account for some lack of efficacy. Therefore one of 
the challenges of PRRS control is the development of tools 
to predict the efficacy of vaccines with greater accuracy.
To date, measurement of humoral immunity (neutral-
izing antibodies) and cell-mediated immunity (IFN-γ 
responses levels) have been used for monitoring PRRSV 
infection [20, 21, 46]. We hypothesized that the generation 
and the maintenance of protective immunity to PRRSV 
Figure 4 Heatmap of probesets showing individual Log2 fold 
gene expression level with the different treatments and the 
pig groups (unvaccinated control, CNTRL; Low Responder, LR; High 
Responder, HR). Pig identification is shown below heatmap: pig 
number 24, 34 and 5 for control pigs; pig number 26, 59 and 61 for 
LR pigs; pig number 16, 21, 38 for HR pigs. Rows, representing gene 
symbols for each probeset except for LOC396781, were ordered by 
hierarchical clustering and columns were displayed ordered by treat‑
ment (mock, in grey; PHA, in orange; vaccine, in blue). Log2 expres‑
sion scale is shown. A red line box highlights heatmap of groups 
treated with vaccine.
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vaccine are a complex process that entails the regulation 
of transcriptional pathways leading to the production of 
neutralizing antibody and the induction of cell-mediated 
immunity. Thus, in the present study we have focused 
primarily in the PRRSV-specific IFN-γ responses after 
vaccination as a mean of discriminating between ani-
mals. The three animals with the most extreme results in 
the ELISPOT were selected. Our results show that in a 
group of cross-bred pigs of the same origin, responses to 
PRRSV vaccination may range from low IFN-γ responses 
and low or nil NA, as in the Low Responders (LR) group, 
to higher IFN-γ responses and moderate titers of NA, in 
the High Responders (HR) group. These differences indi-
cate that inter-individual variability in markers of PRRSV 
vaccine-induced immunity, including neutralizing anti-
body levels and INF-γ responses, may be regulated, at 
least in part by host genetic factors [47]. This observation 
is indeed reminiscent with current trends suggesting that 
host genetic variation in the outcomes of PRRSV infec-
tions occurs in growing pigs as well as during reproduction 
[25]. Specifically, a QTL on chromosome SSC4 was found 
to be associated with viraemia levels and the growth rate in 
experimentally infected pigs [28]. Further, the SNPs defin-
ing this QTL have been shown to be associated with resist-
ance and performance in several independent populations 
[48–50]. Collectively, these studies suggest that immune 
response to PRRSV is likely the results of multigenic influ-
ences and possibly not of a single dominant gene/allele and 
advocate the need for further genetic investigation of the 
host response to PRRSV vaccine.
To further delineate which genes and pathways are 
associated with HR and LR vaccinated pigs we have con-
ducted a genome–wide transcriptional study of PBMCs 
6  weeks post vaccination. The selection of the time-
points was based on the likelihood of having the minimal 
influence with residual vaccine virus in blood [51] and 
to choose a moment in the development of the immune 
response when cell-mediated immunity was more or less 
in a steady state [11, 22].
The number of examined animals per group can repre-
sent a critical factor to reach statistical power for compar-
isons for such studies. Indeed, the high inter-individual 
variability in gene expression of control animals noticed 
using Biolayout Express3D software could explain why 
statistical significance was not achieved among vaccinated 
and unvaccinated groups after vaccine treatment (Table 2; 
Figure  4). However, the results of gene expression after 
vaccine stimulation showed an enrichment of immune-
related genes in the LR and HR vaccinated groups as com-
pared to the unvaccinated controls. Most of these genes, 
CXCL9, CXCL10 and CXCL11 were related with mono-
cyte and T-lymphocyte activation and with interferon-
modulation antiviral responses (CYP3A46, CYP3A29 and 
OAS1) [41, 42]. For this reason we considered that these 
changes in gene expression were potentially biologically 
relevant despite not being selected using the Anova test 
with Partek software. On the other hand and despite the 
limited number of pigs tested, statistical significance was 
reached for the other group comparisons (mock and PHA 
stimulated) suggesting that future transcriptional study of 
vaccine efficacy could benefit from larger number of ani-
mals per experimental group.
Gene regulation in the LR vaccinated group sug-
gested that in those animals there was a functional 
impairment in at least some components of the inflam-
matory response such as CCL2 or IL1A but also that 
transcript levels or transcription of genes encoding some 
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Figure 5 Number of genes categorized by biological processes 
for each animal group. Bars are representing the number of genes 
per category of biological process with a FDR ≤ 5% as shown in 
Additional file 3, for the Low responders (A) and the High responders 
(B) vaccinated groups.
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Table 3 Analysis of upstream regulators using IPA
Data with P value < 0.05 and ¦activation Z‑score¦ ≥2 were considered significant. Information related to this table can be complemented by data reported by 
Additional file 4 which shows target molecules of the whole datasets and associated mechanistic pathway.
Mma_DMAG, 5‑O‑mycolyl‑beta‑araf‑(1→2)‑5‑O‑mycolyl‑alpha‑araf‑(1→1′)‑glycerol [55]; n/a, not applicable (not found in the dataset). The P value of overlap, which 
indicates possible upstream regulators, represents the significance of the overlap between the dataset genes identified and the known targets of transcriptional 
regulators. The activation z‑score was used to infer the state of activation of upstream regulators based on a comparison with a model that assigns random 
regulations.
Upstream regulator High responders Low responders
Activation z‑score P value of overlap Activation z‑score P value of overlap
TNF −3.4 4.93E‑09 −5.9 1.86E‑25
Lipopolysaccharide (LPS) −3.3 5.27E‑10 −6.0 4.09E‑32
IL1B −2.8 1.81E‑09 −5.2 1.08E‑28
NFkB (complex) −2.7 4.98E‑08 −4.5 1.32E‑15
Mma_DMAG −2.6 2.12E‑12 −3.9 6.94E‑20
Immunoglobulin −2.5 1.56E‑09 n/a n/a
IFNG −2.4 1.28E‑06 −4.4 3.36E‑20
Salmonella enterica‑LPS −2.4 1.66E‑08 −3.1 1.61E‑12
poly rI:rC‑RNA −2.4 2.11E‑06 −4.3 1.20E‑16
E. coli B5‑LPS −2.3 1.53E‑07 −4.1 1.33E‑16
STAT3 n/a n/a −4.0 1.82E‑16
IL1A n/a n/a −3.9 2.49E‑22
High responder Low responder
*
*
*
*
*
*
*
*
*
**
*
*
*
*
*
*
*
Figure 6 In silico analysis of the relationship between IFNG and target genes. Based upon the analysis of upstream regulators using IPA 
(see Table 3 and Additional file 4) the predicted relationship between targeted molecules and IFNG in the High responder (HR) and Low responder 
(LR) vaccinated groups are displayed. Ten and 40 predicted relationships were identified with IFNG and target genes in the HR and LR group, respec‑
tively. Red color denotes predicted relationships leading to activation. Blue arrows denote predicted relationship leading to inhibition. Orange 
color denotes inconsistencies with the state of downstream molecule. Grey color denotes effect not predicted. *Represents targeted molecules in 
common between LR and HR vaccinated groups.
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chemokines that act as strong chemotactic compounds 
for T cells, NK cell, dendritic cells and monocytes/
macrophages are affected (CCL17, CCL22, CCL23). 
Interestingly down-regulated transcripts encoding 
guanylate-binding proteins GBP2, 4 and 6 were identi-
fied. Members of the GBP gene family are associated 
with antiviral activity in humans and as discussed previ-
ously by Boddicker et al. [28] they have been highlighted 
as potential candidate genes for the QTL identified on 
SSC4 which explains 15% of the variance in genomic esti-
mated breeding values for viral load and 11% for weight 
gain 42  days post infection [48]. Recently, an intronic 
SNP in GBP5 has been identify as a strong candidate 
causal mutation for the SSC4 QTL that controls varia-
tion in host response to PRRSV [49]. As regards the HR 
pigs, either the lower proportion of inhibited up stream 
regulators of the IFN-γ cascade and the up-regulation of 
transcripts encoding for molecules involved in anti-apop-
tosis mechanisms (P2RY12, VNN1 and IGF1), suggests 
increased chemotactic activity, viral-induced-apoptosis 
resistance and a better induction of cellular immune 
response.
Curiously, HR vaccinated animals presented a down-
regulation of a member of the tumor necrosis fac-
tor superfamily, TNFSF15, and miR181 transcripts. 
TNFSF15 is produced by inflammatory cytokine-stim-
ulated endothelial cells and by TLR ligands-stimulated 
antigen presenting cells, and it is involved in apop-
tosis, cell proliferation and polarization to Th1 and 
Th17 responses [52]. Recently, increased levels in sera 
and genetic polymorphisms of TNFSF15 have been 
observed in inflammatory diseases that are caused by 
altered immunological reactions such as Crohn’s disease 
or ulcerative colitis [52]. As regards to miR181, over-
expression of this molecule has been recently identified 
in minimally PRRSV-permissive cells or tissues, and this 
molecule is able to inhibit  PRRSV  replication by both 
mechanisms: binding to a conserved region in the down-
stream of open reading frame 4 [53] and downregulating 
the PRRSV receptor CD163 in blood monocytes and por-
cine  alveolar macrophages [54]. The fact that TNFSF15 
and miR181 were found down-regulated in HR vacci-
nated pigs is noteworthy and warrant further studies. It is 
possible that these factors may be associated with either 
protective mechanism induced against harmful effects of 
an exacerbated inflammatory response and/or a higher 
cell permissibility to the vaccine virus and thus, better 
priming and immune stimulation.
It is likely that at 6  weeks PV the transcriptional 
response we have measured may have been mostly 
associated with the resolution phase rather than the 
primary response. However, the finding that the tran-
scriptional signature in LR pigs was associated with a 
down-regulation of the IFN-γ response was interest-
ing for several reasons: this specific transcriptional sig-
nature was consistent with the low IFN-γ level found 
in the LR or the HR pigs maybe resolving some of the 
vaccine response. On the other hand, the results of 
the experiment are compatible with either a faster or a 
stronger response in the HR group. In each case, impli-
cations would be a little different. If the differences 
were related just to the intensity, the outcome of vac-
cination in LR could maybe be ameliorated by use of 
adjuvants; if the differences relied in the velocity of the 
immune response this could be more much difficult to 
solve. However, in practical terms, in  situations where 
the risk of entering in contact with the virus are high, 
the point is to achieve the fastest and strongest pos-
sible response. As shown here, at 42  days PV a group 
of animals was far from having that type of immunity 
and this seemed to be related to some elements in the 
genetics of the pig.
In summary, this works showed that variable responses 
to PRRSV vaccination may be the result of the genetic 
characteristics of the host. If this was to be proven in 
future challenge studies, genetic selection of pigs could 
be used to increase resistance to the infection through 
vaccination. Taken together this work advocate the need 
for a greater understanding of the host genomics/genet-
ics of PRRSV vaccine response.
Additional files
Additional file 1. List of regulated transcripts with P value < 0.001, 
FDR < 0.2 and fold change above 2 and below -2 in PBMCs of HR 
and LR pigs are displayed. The lists of transcripts were generated using 
Partek software and only non‑redundant records are shown HR and LR 
vaccinated pigs and HR and LR vaccinated pigs in presence of PHA. To 
enhance the comparison between the HR and LR datasets P value and 
fold change are shown across multiple experimental groups.
Additional file 2. Validation of the microarray data using real time 
qPCR. A subset of 9 regulated transcripts was reassessed using real‑time 
qPCR. Data were used to run a regression analysis between the microarray 
and the real time qPCR experiment and generate the correlation coef‑
ficients R2.
Additional file 3. Gene ontology analysis of the data using DAVID 
bioinformatics resources [39]. Analysis was run to generate the most 
likely gene ontology term for the biological processes, cellular compo‑
nents and molecular functions for each group of regulated transcripts in 
HR and LR vaccinated pigs based on P‑value, number of gene component 
and fold enrichment. Only data with FDR <5% are shown.
Additional file 4. Upstream regulators analysis using Ingenuity 
Pathway Analysis for the HR and LR vaccinated pigs. As described in 
material and methods section the expression dataset for HR and LR pigs 
were analysed independently with Fisher’s exact test. To create this data‑
set, activation z‑score| ≥2 for HR and LR pigs were generated and ranked 
from the highest to the lowest. Data were considered significant with P 
value < 0.05 and ¦activation Z‑score| ≥2. The activation z‑score was used 
to infer the state of activation of upstream regulators based on a compari‑
son with a model that assigns random regulations. Target molecules are 
shown for each upstream regulator.
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